VIRX Viracta Therapeutics
- 0.850
- +0.046+5.71%
Viracta Therapeutics News
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
Viracta Therapeutics Appoints Michael Faerm as Chief Fincl Officer >VIRX
Viracta Therapeutics Appoints Michael Faerm as Chief Fincl Officer >VIRX
RBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
Viracta Therapeutics (VIRX.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.23 dollars, previous value was -0.32 dollars, and expected value was -0.29 dollars.
Viracta Therapeutics (VIRX.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.23 dollars, previous value was -0.32 dollars, and expected value was -0.29 dollars.
Viracta Therapeutics Q1 2024 Adj EPS $(0.23) Beats $(0.35) Estimate
Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.35) by 34.29 percent.
Viracta Therapeutics | 10-Q: Quarterly report
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that Mark Rothera, President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 11:00 a.m. EDT.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersImmutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock
Day One Wins FDA Nod Brain Cancer Therapy, Ojemda
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e
Viracta Therapeutics Is Maintained at Outperform by Oppenheimer
Viracta Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer: Maintaining the Viracta Therapeutics (VIRX.US) rating, adjusted from being superior to better than the market rating, with a target price of $13.00.
Oppenheimer: Maintaining the Viracta Therapeutics (VIRX.US) rating, adjusted from being superior to better than the market rating, with a target price of $13.00.
Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target
Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.
Analysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
BSGM, ENLV and WISA Among Mid-day Movers
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Monday, Viracta Therapeutics Inc (NASDAQ:VIRX) reported topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive
Viracta Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial From Both Arms of the Relapsed or Refractory Epstein-Barr Virus-positive Peripheral T-cell Lymphoma Cohort.
Viracta Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial From Both Arms of the Relapsed or Refractory Epstein-Barr Virus-p
Viracta Therapeutics Reports Positive Results From Stage 1 of Phase 2 Trial for Lymphoma Treatment
NXPL, MGRM and OCX Among Pre-market Losers
Analysis
Price Target
No Data
